Rapid Antimicrobial Susceptibility Testing (RAST): A Quick Guide to Bacterial Sepsis Management

Area of Science:

• Medical Microbiology
• Infectious Diseases
• Clinical Diagnostics

Background:

• Sepsis is a critical global health threat requiring effective diagnostic strategies.
• Current antimicrobial susceptibility testing (AST) methods have long turnaround times (TAT), delaying appropriate treatment.
• Rapid AST methods are crucial for timely intervention and improved patient outcomes.

Purpose of the Study:

• To evaluate the reliability of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) Rapid Antimicrobial Susceptibility Testing (RAST) against standard AST (SAST).
• To establish RAST as a dependable diagnostic tool for managing bacterial sepsis in a clinical setting.
• To assess the impact of RAST on reducing TAT for antibiotic administration.

Main Methods:

• A prospective study involving 53 monobacterial positive blood culture isolates from a tertiary care hospital.
• RAST was performed on positively flagged blood culture bottles following EUCAST RAST 2023 guidelines.
• Results were compared with SAST, with statistical analysis using SPSS software.

Main Results:

• RAST significantly reduced TAT from 47 hours 45 minutes (SAST) to 22 hours 44 minutes.
• High agreement (100%) between RAST and SAST was observed for ceftazidime, ciprofloxacin, ceftazidime-avibactam, cefotaxime, and meropenem (kappa=1.000).
• Minor discrepancies were noted for piperacillin-tazobactam and amikacin, and one major error for trimethoprim-sulfamethoxazole, with high kappa values indicating good agreement.

Conclusions:

• RAST is a reliable and valuable tool for rapid antimicrobial susceptibility testing in sepsis management.
• The reduced TAT offered by RAST supports effective antibiotic stewardship and timely clinical decision-making.
• Implementing RAST can lead to improved patient survival rates through earlier targeted antimicrobial therapy.